About Bioverativ (NASDAQ:BIVV)
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:BIVV
CUSIPN/A
Phone+1-781-6634400
Debt
Debt-to-Equity RatioN/A
Current Ratio2.00%
Quick Ratio1.89%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio27.48
P/E Growth1.96
Sales & Book Value
Annual Sales$1.17 billion
Price / Sales9.72
Cash Flow$2.8754 per share
Price / Cash36.51
Book Value$8.29 per share
Price / Book12.66
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$355.60 million
Net Margins30.43%
Return on Equity40.99%
Return on Assets22.79%
Miscellaneous
Employees460
Outstanding Shares108,220,000
Bioverativ (NASDAQ:BIVV) Frequently Asked Questions
What is Bioverativ's stock symbol?
Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."
How were Bioverativ's earnings last quarter?
Bioverativ Inc (NASDAQ:BIVV) announced its quarterly earnings data on Tuesday, February, 13th. The biotechnology company reported $0.76 EPS for the quarter, beating the Zacks' consensus estimate of $0.75 by $0.01. The biotechnology company earned $328.70 million during the quarter, compared to analysts' expectations of $325.89 million. Bioverativ had a return on equity of 40.99% and a net margin of 30.43%. View Bioverativ's Earnings History.
When is Bioverativ's next earnings date?
What price target have analysts set for BIVV?
13 brokerages have issued 12 month price objectives for Bioverativ's stock. Their forecasts range from $47.00 to $80.00. On average, they expect Bioverativ's share price to reach $65.00 in the next year. View Analyst Ratings for Bioverativ.
What are Wall Street analysts saying about Bioverativ stock?
Here are some recent quotes from research analysts about Bioverativ stock:
- 1. William Blair analysts commented, "We are dropping coverage of Bioverativ , Inc. following the completion of its acquisition by Sanofi (SNY $39.90). Our final rating on Bioverativ was Market Perform." (3/8/2018)
- 2. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (1/8/2018)
- 3. Cowen Inc analysts commented, "Bioverativ reported Q2 revenue of $289MM (+38% Y/Y) versus consensus of." (8/4/2017)
Who are some of Bioverativ's key competitors?
Some companies that are related to Bioverativ include American Airlines Group (AAL), Ctrip (CTRP), Paychex (PAYX), Fifth Third Bank (FITB), Mylan (MYL), Microchip Technology (MCHP), Willis Towers Watson (WLTW), Wynn Resorts (WYNN), Align Technology (ALGN), Cerner (CERN), SBA Communications (SBAC), IHS Markit (INFO), Cintas (CTAS), O'Reilly Auto Parts (ORLY), NetApp (NTAP), Verisk Analytics (VRSK), Dish Network (DISH) and Symantec (SYMC).
Who are Bioverativ's key executives?
Bioverativ's management team includes the folowing people:
- Brian S. Posner, Independent Chairman of the Board (Age 55)
- John G. Cox, Chief Executive Officer, Director (Age 54)
- John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
- Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
- Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
- Richard Brudnick, Executive Vice President - Business Development (Age 60)
- Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
- Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
- Alexander J. Denner Ph.D., Independent Director (Age 47)
- Louis J. Paglia, Independent Director (Age 59)
Has Bioverativ been receiving favorable news coverage?
News headlines about BIVV stock have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bioverativ earned a media sentiment score of 0.19 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 42.41 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Bioverativ?
Shares of BIVV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioverativ's stock price today?
One share of BIVV stock can currently be purchased for approximately $104.98.
How big of a company is Bioverativ?
Bioverativ has a market capitalization of $11.36 billion and generates $1.17 billion in revenue each year. Bioverativ employs 460 workers across the globe.
How can I contact Bioverativ?
Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected]
MarketBeat Community Rating for Bioverativ (BIVV)
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe BIVV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIVV will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bioverativ (NASDAQ:BIVV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Bioverativ in the last 12 months. Their average twelve-month price target is $65.00, suggesting that the stock has a possible downside of 38.08%. The high price target for BIVV is $80.00 and the low price target for BIVV is $47.00. There are currently 12 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.08 | 2.20 | 2.25 | 2.44 |
| Ratings Breakdown: | 0 Sell Rating(s)
12 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
12 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
12 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $65.00 | $64.00 | $62.5714 | $61.2143 |
| Price Target Upside: | 38.08% downside | 39.04% downside | 39.71% downside | 1.65% upside |
Bioverativ (NASDAQ:BIVV) Consensus Price Target History
Bioverativ (NASDAQ:BIVV) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Bioverativ (NASDAQ:BIVV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Bioverativ (NASDAQ BIVV) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 97.18%
Bioverativ (NASDAQ BIVV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/9/2017 | Brian S Posner | Director | Buy | 1,000 | $59.19 | $59,190.00 | 6,693 |  |
| 8/7/2017 | Louis J Paglia | Director | Buy | 2,000 | $59.70 | $119,400.00 | 5,056 | |
| 6/28/2017 | Diantha Duvall | Insider | Sell | 818 | $60.47 | $49,464.46 | 2,128 | |
| 5/30/2017 | Alexander J Denner | Director | Buy | 90,000 | $55.93 | $5,033,700.00 | 5,001 | |
| 5/26/2017 | Louis J Paglia | Director | Buy | 2,000 | $57.76 | $115,520.00 | 3,056 | |
| 5/24/2017 | Brian S Posner | Director | Buy | 2,000 | $53.86 | $107,720.00 | 4,993 | |
(Data available from 1/1/2013 forward)
Bioverativ (NASDAQ BIVV) News Headlines
| Source: |
|
Bioverativ (NASDAQ:BIVV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bioverativ (NASDAQ:BIVV) Income Statement, Balance Sheet and Cash Flow Statement
Bioverativ (NASDAQ BIVV) Stock Chart for Monday, April, 23, 2018
Loading chart…
